For LEMD1, with the update of studies, its overexpression has been proved in a series of malignancies, such as prostate cancer, oral squamous cell carcinoma, gastric cancer and colorectal cancer [5–8]. This evidence concerns the gene LEMD1 and prostate carcinoma.